-

11:26:47 PM

UCBJY Stock News

UCBJY - UCB SA

05/23/22 12:16 PM

OTC : UCBJY

clinical trial

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and symptoms across the full spectrum of axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) Treatment with bimekizumab

RHEA-AI

positive

05/23/22 12:07 PM

OTC : UCBJY

clinical trial

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively A higher proportion of patients treated with bimekizumab vs. placebo achieved

RHEA-AI

neutral

05/10/22 7:00 AM

OTC : UCBJY

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with consistent statistical significance and clinical relevance Regulatory submissions for zilucoplan and rozanolixizumab are planned for later this year

RHEA-AI

neutral

05/02/22 1:30 PM

OTC : UCBJY

clinical trial

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS patients compared to placebo 1 The peer-reviewed published data reinforce the clinical profile of FINTEPLA and its value as a new and important

RHEA-AI

neutral

04/01/22 10:00 AM

OTC : UCBJY

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological diseases New data focused on epilepsy and Parkinson's disease (PD), including real-world use of BRIVIACT ® (brivaracetam) CV, long-term use of FINTEPLA ®

RHEA-AI

neutral

03/28/22 1:00 AM

OTC : UCBJY

fda approval

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

FINTEPLA ® has demonstrated efficacy in the most difficult-to-treat seizure types, 1 ,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground, with a high likelihood of injury 3 LGS is a severe childhood-onset developmental and epileptic

RHEA-AI

neutral

03/26/22 10:30 AM

OTC : UCBJY

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Eleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis Pooled data from five Phase 3/ 3b trials showed that more than eight out of 10 patients who achieved complete skin clearance with bimekizumab at week 16, and entered open-label

RHEA-AI

neutral

02/04/22 7:00 AM

OTC : UCBJY

clinical trial

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE ( NCT04115293) trial i evaluating its investigational treatment zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement

RHEA-AI

neutral

01/21/22 8:50 AM

OTC : UCBJY

clinical trial

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis, who were

RHEA-AI

positive

01/19/22 1:00 AM

OTC, Nasdaq : UCBJY, ZGNX

acquisition

UCB to acquire Zogenix

Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global

RHEA-AI

neutral